FDA Biosimilar Development Guidance Targets Treatment Costs
Learn how the new FDA biosimilar development guidance can significantly lower biologic medicine costs and improve accessibility.
Aspen Pharmacare Debt-Free: Strategic Shift To GLP-1 Injectables
Aspen Pharmacare Debt-Free marks a pivotal moment in its history as it shifts focus toward GLP-1 injectables like semaglutide.
Local Pharmaceutical Manufacturing and Health Security
Join the discussion on local pharmaceutical manufacturing versus cost in South Africa's contentious R15.5bn AIDS drug tender situation.
Competition Commission Pharma Probe Expands Scope
The Competition Commission has initiated an early-stage investigation into several pharmaceutical manufacturers following a complaint from the national health department. The companies named include Ascendis, Pharma Q and Sonke, all of which supply medicines to the state…. Membership Required You must be a member to access this content.View Membership LevelsAlready a member? Log in here...
Healthcare Investment Drives Growth and Productivity
Discover how healthcare investment drives growth, linking public health to stronger GDP performance in emerging markets.
1.4% SEP Increase Impacts Pharmaceutical Investment
Understanding the 1.4% SEP increase: why the pharmaceutical sector is urging a reconsideration of the price cap.
Illegal weight loss injections: The rising black market crisis
Illegal weight loss injections are flooding the local market as high costs and obesity rates drive a dangerous market for GLP-1 agonists.
Hetero Price Collusion Probe and Its Implications
Uncover the details of the Hetero price collusion probe as the Competition Commission examines key drug procurement allegations.
HIV Drug Tender Facing Legal Challenge from Hetero SA
Hetero SA challenges the HIV drug tender decision in court, claiming exclusion from vital antiretroviral supply contracts.
US Drug Prices Under Trump’s New Pharma Deals
Examine the ongoing battle over US drug prices and the potential effects of Trump's recent pharma agreements on affordability.